Abstract: This invention provides novel bicyclic compounds of Formula (I): 1

Abstract: This invention provides compounds of Formula I having the structure wherein R1, R2 are both hydrogen or form a bond, or are each, independently, alkyl of 1-6 carbon atoms or aryl of 6-12 carbon atoms; m=0-10; n=1-3; and p=0-10; with the proviso that m+p is less than or equal to 15; or a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia.

Abstract: The compounds of the formulae: ##STR1## in which R.sup.1 is alkyl, perfluoroalkyl, alkoxy, perfluoroalkoxy of 1 to 6 carbon atoms, alkylthio, perfluoroalkylthio, alkylsulfinyl, alkylamino, halo, alkanoyl, 1-hydroxyalkyl or 1-(hydroxyimino) alkyl;R.sup.2 is hydrogen or alkyl of 1 to 3 carbon atoms;R.sup.3 is alkyl of 1 to 3 carbon atoms;R.sup.4 is alkyl of 1 to 6 carbon atoms;or a pharmaceutically acceptable salt thereof, are antihyperglycemic agents.

Abstract: The compound of the formula: ##STR1## in which the dotted lines represent two sites of unsaturation appropriately located based on the identity of R.sup.2, R.sup.3 and R.sup.4 and, R.sup.1 is alkyl, perfluoroalkyl, alkoxy, perfluoroalkoxy, alkylthio, perfluoroalkylthio, alkylsulfinyl, alkylamino, halo, alkanoyl, 1-hydroxyalkyl or (1-hydroxyimino) alkyl; R.sup.2 is hydrogen or alkyl; R.sup.3 is hydrogen or alkyl; R.sup.4 is hydrogen or alkyl; n is 0 or 1; or a pharmaceutically acceptable salt thereof, are antihyperglycemic agents.

Abstract: The compounds of the formula: ##STR1## in which the dotted lines represent optional unsaturation when n is 1 or 2 and X is CR.sup.5, Y is CR.sup.6 or X or Y are N; R.sup.1 is hydrogen, alkyl, aryl or arylalkyl; R.sup.2 is hydrogen, alkyl, aryl or arylalkyl; R.sup.3 is alkyl, perfluoromethyl or alkoxy; R.sup.4 is halogen, alkyl or alkoxy; X is CR.sup.5, O, S or N, in which R.sup.5 is hydrogen, halogen, alkyl, or alkoxy; Y is CR.sup.6, O, S or N, in which R.sup.6 is hydrogen, halogen, alkyl or alkoxy; n is one of the integers 0, 1 or 2; m is one of the integers 0, 1, 2, or 3; or a pharmaceutically acceptable salt thereof, with the provisos that one of X and Y is O,S or N and R.sup.3 is other than alkyl when n and m are 0 and X and Y are O, are useful hypolglycemic agents in the treatment of non-insulin dependent diabetes melitus.

Abstract: The compounds of the formula: ##STR1## in which the dotted lines represent optional unsaturation when X is CR.sup.5, Y is CR.sup.6 or X or Y are N; R.sup.1 is hydrogen, alkyl, aryl or arylalkyl; R.sup.2 is hydrogen, alkyl, aryl or arylalkyl; R.sup.3 is alkyl, perfluoromethyl or alkoxy; R.sup.4 is halogen, alkyl or alkoxy; X is CR.sup.5, O, S or N, in which R.sup.5 is hydrogen, halogen, alkyl, or alkoxy; Y is CR.sup.6, O, S or N, in which R.sup.6 is hydrogen, halogen, alkyl or alkoxy; n is one of the integers 0, 1 or 2; m is one of the integers 0, 1, 2 or 3; or a pharmaceutically acceptable salt thereof, are useful hypoglycemic agents in the treatment of non-insulin dependent diabetes mellitus.

Abstract: Compounds of the formula: ##STR1## in which R is a substituted or unsubstituted monocyclic or bicyclic alkyl group containing from 3 to 8 ring carbon atoms, wherein any substituent is alkyl of 1 to 3 carbon atoms, oxo, hydroxy, carboxy or when the hydroxy and carboxy substituents taken together they form a 1,3-carbonyloxy lactone ring closed structure;n is one of the integers 0, 1, 2 or 3;X is --O--, ##STR2## or --SO.sub.2 NH--; and Z is .dbd.CH-- or --N.dbd.;or a pharmaceutically acceptable salt thereof, are anti-hyperglycemic agents.

Abstract: Compounds of the formula: ##STR1## where R is hydrogen or A--(CF.sub.2).sub.m --CH.sub.2 --; A is --F or --H; n is an integer from 1 to 10, inclusive; m is an integer from 0 to 9, inclusive; p is an integer from 0 to 4, inclusive; and Y is hydrogen, halo, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, or hydroxy; or a pharmaceutically acceptable salt thereof. The compounds are useful as anti-hyperglycemic and anti-hyperinsulinemic agents.

Abstract: There are disclosed compounds having the formula ##STR1## wherein X is CR or N when n=1; orX is O, S, NR or CR when n=0;R is hydrogen or lower alkyl;Y is --CH.sub.2 --, --S--, --O-- or ##STR2## and A is ##STR3## Z is CH or N; R.sup.1 is halo or trifluoromethyl;R.sup.2 is hydrogen or halo;R.sup.3 is hydrogen or halo;with the proviso that when A is naphthyl, Y is --O-- and n=0, X is other than S; and their use in the treatment of inflammatory conditions and in the treatment of leukotriene-medicated naso-bronchial obstructive passageway conditions.

Abstract: The compounds: ##STR1## in which R is hydrogen, lower alkyl, phenyl or benzyl, and R.sup.2 is hydrogen or lower alkyl, or a pharmaceutically acceptable salt thereof, are useful hypoglycemic and hypoinsulinemic agents for the treatment of diabetes mellitus and cardiovascular disease states involved in elevated insulin levels such as atherosclerosis.

Abstract: There are disclosed compounds of the formula ##STR1## wherein X is OR.sup.2, SR.sup.2, N(R.sup.2).sub.2 or halo;W is --CH.sub.2 --, ##STR2## Y is --CH.sub.2 O--, --OCH.sub.2 --, --CH.sub.2 S--, --SCH.sub.2 --, ##STR3## m is 0-6; n is 0-6;p is 1-3;A is O or S;B is OR.sup.2, SR.sup.2 or N(R.sup.2).sub.2 ;R.sup.1 is hydrogen, loweralkyl, loweralkoxy or halo;R.sup.2 is hydrogen or loweralkyl;and the pharmaceutically acceptable salts thereof, and their use in the treatment of leukotriene-mediated naso-bronchial obstructive airpassageway conditions, such as allergic rhinitis, allergic bronchial asthma and the like.